Retatrutide

Retatrutide is a novel synthetic peptide acting as a triple agonist at the GLP-1, GIP, and glucagon receptors. It represents the latest generation of multi-target incretin-based compounds and has been the focus of significant clinical research into metabolic regulation, body composition, and glycemic control. Investigated for its potential in obesity research and type 2 diabetes models, retatrutide engages three distinct pathways simultaneously. Supplied as lyophilized powder for laboratory reconstitution and research use.

This product is sold for laboratory research use only and is not intended for human consumption, therapeutic, diagnostic, or veterinary use. Statements describing research applications refer to academic and preclinical literature and do not constitute claims of efficacy or safety for any application.